Efficacy and safety of adalimumab for the Crohn's disease: A systematic review and meta-analysis of published randomized placebo-controlled trials

European Journal of Clinical Pharmacology

Volumn 70, Issue 8, 2014, Pages 907-914

  Song, Yun Na ^a   Zheng, Ping ^b   Xiao, Jun Hua ^b   Lu, Zhan Jun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Tongji University   (China)

Author keywords

Adalimumab; Crohn's disease; Efficacy and safety; Meta analysis; Randomized controlled trial; Tumor necrosis factor blocker

Indexed keywords

ADALIMUMAB; ANTIINFLAMMATORY AGENT; INFLIXIMAB; MONOCLONAL ANTIBODY;

CROHN DISEASE; HUMAN; INTESTINAL FISTULA; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; HUMANS; INTESTINAL FISTULA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84905091673     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-014-1702-1     Document Type: Review

References (38)

1. Baumgart DC, Carding SR (2007) Inflammatory bowel disease: cause and immunobiology. Lancet 369:1627-1640 (Pubitemid 46722636)
2. Cassinotti A, Ardizzone S, Porro GB (2008) Adalimumab for the treatment of Crohn's disease. Biologics 2:763-777
3. Juan J, Estiarte R, Colome E et al (2003) Burden of illness of Crohn's disease in Spain. Dig Liver Dis 35:853-861 (Pubitemid 41070490)
4. Molodecky NA, Soon IS, Rabi DMet al (2012) Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142:46-54
5. Shivananda S, Lennard-Jones J, Logan R et al (1996) Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 39:690-697 (Pubitemid 26426470)
6. Pajares JM, Gisbert JP (2001) Epidemiology of inflammatory bowel disease in Spain. A systematic review. Rev Esp Enferm Dig 93:9-20
7. Saro Gismera C, Lacort Fernandez M, Arguelles Fernandez G et al (2000) Incidenciay prevalencia de la enfermedad inflamatoria intestinal en Gijo ' n, Asturias, Espa-ñ a. Gastroenterol Hepatol 23:322-327
8. Zeng Z, Zhu Z, Yang Y et al (2013) Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong Province, China: a prospective population-based study. J Gastroenterol Hepatol 28:1148-1153
9. Shin DH, Sinn DH, Kim YH et al (2011) Increasing incidence of inflammatory bowel disease among young men in Korea between 2003 and 2008. Dig Dis Sci 56:1154-1159
10. Sood A, Midha V, Sood N et al (2003) Incidence and prevalence of ulcerative colitis in Punjab, North India. Gut 52:1587-1590 (Pubitemid 37363442)
11. Yao T, Matsui T, Hiwatashi N (2000) Crohn's disease in Japan: diagnostic criteria and epidemiology. Dis Colon Rectum 43(Suppl):S85-S93
12. Wilkins T, Jarvis K, Patel J (2011) Diagnosis and management of Crohn's disease. Am Fam Physician 84:1365-1375
13. Ardizzone S, Bianchi Porro G (2005) Biologic therapy for inflammatory bowel disease. Drugs 65:2253-2286 (Pubitemid 41571985)
14. Peyrin-Biroulet L, Deltenre P, de Suray N et al (2008) Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 6:644-653 (Pubitemid 351783447)
15. Van Assche G, Vermeire S, Rutgeerts P (2010) The potential for disease modification in Crohn's disease. Nat Rev Gastroenterol Hepatol 7:79-85
16. D' Haens G, Van Deventer S, Van Hogezand R et al (1999) Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 116:1029-1034 (Pubitemid 29203012)
17. D' Haens G, Noman M, Baert F et al (2002) Endoscopic healing after infliximab treatment for Crohn's disease provides a longer time to relapse. Gastroenterology 122(Suppl 4):A-618
18. Cassinotti A, Travis S (2009) Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. Inflamm Bowel Dis 15:1264-1275
19. Baert F, Noman M, Vermeire S et al (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348:601-608 (Pubitemid 36204954)
20. Hanauer SB, Wagner CL, Bala M et al (2004) Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2:542-553 (Pubitemid 38834038)
21. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D et al (2006) Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130:323-333, quiz 591
22. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R et al (2007) Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 146:829-838 (Pubitemid 351650483)
23. Watanabe M, Hibi T, Lomax KG, Paulson SK, Chao J, Alam MS et al (2012) Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. J Crohn's Colitis 6:160-173
24. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R et al (2007) Adalimumab for maintenance of clinical response and remission in patients with Crohn 's disease: the CHARM trial. Gastroenterology 132:52-65 (Pubitemid 46108762)
25. Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF et al (2012) Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 142(1102-1111):e2
26. Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG et al (2007) Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 56:1232-1239 (Pubitemid 47300424)
27. Colombel JF, Schwartz DA, SandbornWJ, Kamm MA, D'Haens G, Rutgeerts P et al (2009) Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut 58:940-948
28. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1-12 (Pubitemid 26120810)
29. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M et al (1998) Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 352:609-613 (Pubitemid 28380142)
30. Dewint P, Hansen BE, Verhey E et al (2014) Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut 63:292-299
31. Present DH, Rutgeerts P, Targan S et al (1999) Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340:1398-1405 (Pubitemid 29205403)
32. Targan SR, Hanauer SB, van Deventer SJ et al (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337:1029-1035
33. Behm BW, Bickston SJ (2008) Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev: CD006893
34. Abreu MT (2007) Crohn's disease in patients who fail infliximab therapy: what does the future hold? Rev Gastroenterol Disord 7 (Suppl 1):S20-S26
35. Hanauer SB, Feagan BG, Lichtenstein GR et al (2002) Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359:1541-1549 (Pubitemid 34621118)
36. Fichera A, Michelassi F (2007) Surgical treatment of Crohn's disease. J Gastrointest Surg Off J Soc Surg Aliment Tract 11:791-803
37. Barthel HR, Gille T, Halbsguth A et al (2005) Successful treatment with adalimumab in infliximab-resistant Crohn 's disease. J Gastroenterol Hepatol 20:1464-1465 (Pubitemid 43960853)
38. Colombel JF, Rutgeerts PJ, Sandborn WJ et al (2014) Adalimumab induces deep remission in patients with Crohn 's disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 12:414-422, e5